TY - JOUR
T1 - Rhabdomyolysis due to combined therapy with cerivastatin and diclofenac
AU - Schechner, Vered
AU - Hershcovici, Tiberiu
AU - Beigel, Yitzhak
PY - 2003
Y1 - 2003
N2 - Objective: To describe the occurrence of severe rhabdomyolysis and acute renal failure in a patient treated concomitantly with cerivastatin and diclofenac. Case Summary: A 73-year-old white man with mild chronic renal failure, treated with cerivastatin for hypercholesterolemia, received intramuscular injections of diclofenac for low-back pain. A few days later, severe muscle weakness and acute renal failure developed. Laboratory tests confirmed severe rhabdomyolysis. Diclofenac and cerivastatin were discontinued, and treatment with forced diuresis and urine alkalinization was started. Twenty-four days later, serum creatine phosphokinase and urinary function returned to baseline, and the muscle weakness improved. Discussion: Rhabdomyolysis is a well-known adverse effect of statins. According to recent reports, it occurs more frequently with cerivastatin than with other statins. Nevertheless, the interaction between cerivastatin (or other statins) and diclofenac as a trigger for rhabdomyolysis has never been reported. Conclusions: Coadministration of diclofenac (and perhaps other nonsteroidal antiinflammatory drugs) with cerivastatin (and perhaps other statins) should be done cautiously, especially in the presence of renal failure, under close monitoring of renal function and muscle enzyme levels.
AB - Objective: To describe the occurrence of severe rhabdomyolysis and acute renal failure in a patient treated concomitantly with cerivastatin and diclofenac. Case Summary: A 73-year-old white man with mild chronic renal failure, treated with cerivastatin for hypercholesterolemia, received intramuscular injections of diclofenac for low-back pain. A few days later, severe muscle weakness and acute renal failure developed. Laboratory tests confirmed severe rhabdomyolysis. Diclofenac and cerivastatin were discontinued, and treatment with forced diuresis and urine alkalinization was started. Twenty-four days later, serum creatine phosphokinase and urinary function returned to baseline, and the muscle weakness improved. Discussion: Rhabdomyolysis is a well-known adverse effect of statins. According to recent reports, it occurs more frequently with cerivastatin than with other statins. Nevertheless, the interaction between cerivastatin (or other statins) and diclofenac as a trigger for rhabdomyolysis has never been reported. Conclusions: Coadministration of diclofenac (and perhaps other nonsteroidal antiinflammatory drugs) with cerivastatin (and perhaps other statins) should be done cautiously, especially in the presence of renal failure, under close monitoring of renal function and muscle enzyme levels.
UR - http://www.scopus.com/inward/record.url?scp=0038720056&partnerID=8YFLogxK
U2 - 10.1177/875512250301900303
DO - 10.1177/875512250301900303
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0038720056
SN - 8755-1225
VL - 19
SP - 219
EP - 221
JO - Journal of Pharmacy Technology
JF - Journal of Pharmacy Technology
IS - 4
ER -